THAR Latest Report

Financial Performance

At the end of 2024, Tharimmune's operating revenue was -3847464 yuan, a significant year-on-year decrease from -2531156 yuan at the end of 2023. The negative value indicates that the company is facing difficulties in its operations and has failed to achieve positive operating revenue, which may be due to insufficient market demand or internal management issues.

Key Financial Data

1. The operating revenue in 2024 was -3847464 yuan, indicating the company's continued losses in revenue.

2. Research and development expenses increased significantly to 2085459 yuan, up from 992725 yuan in 2023, showing the company's investment in new product development but unable to convert it into revenue in the short term.

3. Marketing and management expenses increased to 1762005 yuan, up from 1538431 yuan in 2023, further increasing the company's cost pressure.

Industry Comparison

1. Overall industry analysis: The overall industry may be affected by macroeconomic fluctuations, intensified competition or policy changes, leading to a general decline in operating revenue. The performances of Titan Technology and Morningstar Biotechnology show the intensity of industry competition and the insufficiency of market demand.

2. Peer evaluation analysis: Tharimmune's negative operating revenue situation compared to other companies in the industry may indicate a decline in its market share or a misguided business strategy. Titan Technology managed to achieve a slight growth in a relatively difficult market environment, while Tharimmune failed to reverse the trend.

Summary

The financial report shows that Tharimmune's operating revenue has continued to be negative, mainly affected by declining market demand, rising costs, and increased research and development expenses. The company's financial health is in question, and urgent improvement of its business strategy and market positioning is needed.

Opportunities

1. Tharimmune is advancing the development of antibody technology, especially in immunotherapy, indicating the industry's growing demand for new therapies.

2. The company is conducting the first-stage clinical trial of TH104, which could bring positive signals for future product releases.

3. The industry's upgrading demand for high-end intelligent products may provide opportunities for Tharimmune's product innovation.

Risks

1. The continuous increase in research and development expenses may lead to operating losses and cash flow pressure, affecting the company's long-term development.

2. Uncertainty in the market environment and policy changes may make it difficult for Tharimmune to promote its products and penetrate the market, increasing operating risks.

3. Intensified industry competition may lead to further declines in market share, affecting the company's revenue and profitability.